Dr. Reddy's Laboratories Limited share price today

Dr. Reddy's Laboratories Limited's share price was $14.77 at the close on 4 November 2026. It has been stalling near its high for 3 weeks. That is 11.6% above its average price over the last 200 trading days.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Dr. Reddy's Laboratories Limited is in stage 3. The phase helps read everything below.

In the last 52 weeks it traded between $12 and $15, and at that close it sat 83% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 4 weeks in a row.

Over the last 10 years the share price moved +38% while the S&P 500 moved +261%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Dr. Reddy's Laboratories Limited declared INR 8.00 per local share for Mar 2026. It reports in Indian rupees, and one US-listed share can stand for several local shares, so we do not set this against the dollar price or show a yield.

Dr. Reddy's Laboratories Limited is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Dr. Reddy's Laboratories Limited earned INR 9.3 B of net profit in the Sep 2026 quarter, −35.6% on the same quarter a year earlier. Full-year FY26 profit was INR 42.9 B. Over 4 years profit has grown 16.1% a year on average. That is 10.7% of the quarter's revenue. The same quarter a year earlier earned INR 14.4 B.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was INR 42.9 B (−24.2% on the year before).

Why profit moved: revenue changed −1.5% on a year earlier and the margin moved −5.6 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed −51.2% and revenue −3.6%. Profit is growing slower than sales: rising costs are taking part of the growth.

This company reports in Indian rupees, not US dollars, so the money charts are left out here. The figures in the text are in that currency (INR); nothing is converted.

Dr. Reddy's Laboratories Limited reported INR 86.7 B of revenue in the Sep 2026 quarter, −1.5% on the same quarter a year earlier. Over 4 years it has grown 11.9% a year on average. The last full year, FY26, came in at INR 336 B. The last four reported quarters add to INR 330 B.

Revenue is everything the company billed its customers in the period.

The quarterly figures for FY22 do not add up to the full-year total on file, so those quarters are left out of the charts and sums.

FY26 revenue was INR 336 B, +3.2% on the year before.

Recent pace: the last four quarters grew −3.6% on average, against 11.9% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew −3.6%, against +4.9% a year over the last 8 quarters (rolling over); profit over the last 12 months grew −52.3%, against −27.6% a year (rolling over).

This company reports in Indian rupees, not US dollars, so the money charts are left out here. The figures in the text are in that currency (INR); nothing is converted.

Dr. Reddy's Laboratories Limited's operating margin was 14.7% in the Sep 2026 quarter, 5.6 percentage points lower than the same quarter a year ago. Across 5 years it has been between 14.7% and 23.4%. The latest quarter is within that range.

Operating margin is what is left from every INR 100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −5.6 percentage points on the year while gross margin changed −2.6 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 96% of Dr. Reddy's Laboratories Limited's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in INR 56.8 B of operating cash against INR 42.9 B of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

After INR 23.3 B of spending on assets, INR 33.4 B was left over as free cash.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

This company reports in Indian rupees, not US dollars, so the money charts are left out here. The figures in the text are in that currency (INR); nothing is converted.

Dr. Reddy's Laboratories Limited does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent INR 67.2 B on assets over the last 3 years. Averaged over those years that is 6.7% of FY26 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: INR 67.2 B over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

This company reports in Indian rupees, not US dollars, so the money charts are left out here. The figures in the text are in that currency (INR); nothing is converted.

Dr. Reddy's Laboratories Limited's P/E is 41.5×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple.

Dr. Reddy's Laboratories Limited's business is getting worse. Revenue and profit growth are shrinking: revenue growth is −3.6% in the latest quarter, against +16.6% at its best in 12 quarters, with ROCE falling at 7.8%. This is based on 12 quarters of 3 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind.

This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Dr. Reddy's Laboratories Limited earned a ROE of 11% in FY26. Its return on capital used (ROIC) is 0.6 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 12.8% net margin and 0.58× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY26): a 12.8% net margin × 0.58× asset turnover × 1.52× leverage (assets divided by equity) ≈ 11.3% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 6.2% − 5.6% = +0.6 percentage points. The 5.6% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error.

The 6.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 11.0%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Dr. Reddy's Laboratories Limited has total debt of INR 72.3 B against shareholder equity of INR 389 B as of Sep 2026, so its debt is 0.19× its equity, which is very little. Year by year, that ratio went from 0.18 in FY22 to 0.20 in FY26.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

So the returns on this page come from the business, not from borrowed money.

This company reports in Indian rupees, not US dollars, so the money charts are left out here. The figures in the text are in that currency (INR); nothing is converted.

We have no ownership or short-position figures for Dr. Reddy's Laboratories Limited, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 8.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

For Dr. Reddy's Laboratories Limited, the Z-score is 5.29. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 5.29 is well clear of the danger zone, so the balance sheet is not the risk here.

There is no score against its industry: Dr. Reddy's Laboratories Limited is not among the largest members shown in this industry comparison for Drug Manufacturers - Specialty & Generic.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not among the largest members shown in this industry comparison.

Dr. Reddy's Laboratories Limited is the 9th largest of 51 Drug Manufacturers - Specialty & Generic companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Viatris Inc., Neurocrine Biosciences, Inc. and Elanco Animal Health Incorporated. Just below it: Alkermes plc, Kiniksa Pharmaceuticals International, plc and Amneal Pharmaceuticals, Inc.

Drug Manufacturers - Specialty & Generic companies close in size

6. Viatris Inc. $22.1 billion
7. Neurocrine Biosciences, Inc. $16.8 billion
8. Elanco Animal Health Incorporated $12.6 billion
9. Dr. Reddy's Laboratories Limited $12.1 billion
10. Alkermes plc $7.7 billion
11. Kiniksa Pharmaceuticals International, plc $7.6 billion
12. Amneal Pharmaceuticals, Inc. $6.9 billion

All 51 Drug Manufacturers - Specialty & Generic companies, largest first

Companies close in size in other industries

824. SiTime Corporation $12.1 billion · Semiconductors
825. DaVita Inc. $12.1 billion · Medical Care Facilities
826. Dr. Reddy's Laboratories Limited $12.1 billion
827. FactSet Research Systems Inc. $12.1 billion · Financial Data & Stock Exchanges
828. Mueller Industries, Inc. $12 billion · Metal Fabrication

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.